Long-term remissions of young patients with high-risk follicular lymphoma after first-line autologous stem cell transplantation: Three case reports
This study aims to speculate the rationality of ASCT as first-line treatment, through 3 cases and review of the literature.
Patient concerns:
3 young-adult patients with FL received ASCT as first-line treatment.
Diagnosis:
All the 3 patients were no more than 30 years old and the diagnosis of FL was confirmed by histopathological and immunohistochemical evaluations. They all had multi-organ involvements, and two of them presented with a “leukemic-like” manifestation. Compared with those in the previous literatures, the 3 patients were relatively younger and had more invasive clinical features.
Interventions:
The 3 patients received combined chemotherapy plus rituximab, followed by first-line ASCT.
Outcomes:
All the 3 patients got complete remission and minimal residual disease negativity after ASCT, The median follow-up time was 109 (97–117) months, and all of them were in remission more than 8 years after transplant.
Lessons:
Guidelines for FL are mainly based on elderly patients, but are not suitable enough for all, especially for the young FL patients. For young patients with certain high-risk FL, first-line ASCT does not go against the guidelines, and should be recommended individually.
Source: Medicine - Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research
More News: Chemotherapy | Internal Medicine | Lessons | Lymphoma | Rituxan | Stem Cell Therapy | Stem Cells | Study | Transplants